Does the media refer more to KNSA or AKTS?

In the previous week, Kiniksa Pharmaceuticals International had 3 more articles in the media than Aktis Oncology. MarketBeat recorded 8 mentions for Kiniksa Pharmaceuticals International and 5 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 1.06 beat Kiniksa Pharmaceuticals International's score of 0.49 indicating that Aktis Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals International 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aktis Oncology 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor INDV or AKTS?

In the previous week, Aktis Oncology had 1 more articles in the media than Indivior. MarketBeat recorded 5 mentions for Aktis Oncology and 4 mentions for Indivior. Aktis Oncology's average media sentiment score of 1.06 beat Indivior's score of 0.22 indicating that Aktis Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Aktis Oncology 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CRSP or AKTS?

In the previous week, CRISPR Therapeutics had 4 more articles in the media than Aktis Oncology. MarketBeat recorded 9 mentions for CRISPR Therapeutics and 5 mentions for Aktis Oncology. CRISPR Therapeutics' average media sentiment score of 1.11 beat Aktis Oncology's score of 1.06 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aktis Oncology 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AKTS or MANE more profitable?

Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Veradermics N/A N/A N/A

Does the media favor AKTS or MANE?

In the previous week, Aktis Oncology and Aktis Oncology both had 5 articles in the media. Aktis Oncology's average media sentiment score of 1.06 beat Veradermics' score of 0.39 indicating that Aktis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AKTS or LEGN?

In the previous week, Aktis Oncology had 1 more articles in the media than Legend Biotech. MarketBeat recorded 5 mentions for Aktis Oncology and 4 mentions for Legend Biotech. Aktis Oncology's average media sentiment score of 1.06 beat Legend Biotech's score of 0.41 indicating that Aktis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Aktis Oncology (AKTS) Competitors

$23.89 -0.12 (-0.50%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$23.88 -0.01 (-0.04%)

As of 07/24/2026 07:34 PM Eastern

Compare

AKTS vs. KNSA, INDV, CRSP, MANE, and LEGN

Should you buy Aktis Oncology stock or one of its competitors? MarketBeat compares Aktis Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aktis Oncology include Kiniksa Pharmaceuticals International (KNSA), Indivior (INDV), CRISPR Therapeutics (CRSP), Veradermics (MANE), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry.

How does Aktis Oncology compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Aktis Oncology (NASDAQ:AKTS) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Comparatively, 3.3% of Aktis Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Aktis Oncology's net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Aktis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Aktis Oncology	N/A	N/A	N/A

In the previous week, Kiniksa Pharmaceuticals International had 3 more articles in the media than Aktis Oncology. MarketBeat recorded 8 mentions for Kiniksa Pharmaceuticals International and 5 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 1.06 beat Kiniksa Pharmaceuticals International's score of 0.49 indicating that Aktis Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aktis Oncology	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kiniksa Pharmaceuticals International has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$754.05M	6.41	$59.01M	$0.90	69.82
Aktis Oncology	$8.28M	154.14	-$63.73M	-$0.38	N/A

Kiniksa Pharmaceuticals International currently has a consensus price target of $68.00, indicating a potential upside of 8.21%. Aktis Oncology has a consensus price target of $34.60, indicating a potential upside of 44.83%. Given Aktis Oncology's higher probable upside, analysts plainly believe Aktis Oncology is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Kiniksa Pharmaceuticals International beats Aktis Oncology on 12 of the 15 factors compared between the two stocks.

How does Aktis Oncology compare to Indivior?

Indivior (NASDAQ:INDV) and Aktis Oncology (NASDAQ:AKTS) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Indivior has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.29B	3.83	$210M	$1.95	20.78
Aktis Oncology	$8.28M	154.14	-$63.73M	-$0.38	N/A

60.3% of Indivior shares are held by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are held by institutional investors. 0.7% of Indivior shares are held by company insiders. Comparatively, 3.3% of Aktis Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Indivior has a net margin of 19.44% compared to Aktis Oncology's net margin of 0.00%. Aktis Oncology's return on equity of 0.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
Aktis Oncology	N/A	N/A	N/A

In the previous week, Aktis Oncology had 1 more articles in the media than Indivior. MarketBeat recorded 5 mentions for Aktis Oncology and 4 mentions for Indivior. Aktis Oncology's average media sentiment score of 1.06 beat Indivior's score of 0.22 indicating that Aktis Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aktis Oncology	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Indivior presently has a consensus price target of $43.67, suggesting a potential upside of 7.74%. Aktis Oncology has a consensus price target of $34.60, suggesting a potential upside of 44.83%. Given Aktis Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Aktis Oncology is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Aktis Oncology beats Indivior on 9 of the 16 factors compared between the two stocks.

How does Aktis Oncology compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Aktis Oncology (NASDAQ:AKTS) are both pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Aktis Oncology has higher revenue and earnings than CRISPR Therapeutics. Aktis Oncology is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,278.86	-$581.60M	-$6.22	N/A
Aktis Oncology	$8.28M	154.14	-$63.73M	-$0.38	N/A

CRISPR Therapeutics presently has a consensus price target of $67.78, suggesting a potential upside of 45.63%. Aktis Oncology has a consensus price target of $34.60, suggesting a potential upside of 44.83%. Given CRISPR Therapeutics' higher possible upside, research analysts clearly believe CRISPR Therapeutics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 3.3% of Aktis Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, CRISPR Therapeutics had 4 more articles in the media than Aktis Oncology. MarketBeat recorded 9 mentions for CRISPR Therapeutics and 5 mentions for Aktis Oncology. CRISPR Therapeutics' average media sentiment score of 1.11 beat Aktis Oncology's score of 1.06 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aktis Oncology	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aktis Oncology has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. Aktis Oncology's return on equity of 0.00% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Aktis Oncology	N/A	N/A	N/A

Summary

CRISPR Therapeutics beats Aktis Oncology on 8 of the 15 factors compared between the two stocks.

How does Aktis Oncology compare to Veradermics?

Aktis Oncology (NASDAQ:AKTS) and Veradermics (NYSE:MANE) are both manufacturing companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

28.8% of Aktis Oncology shares are owned by institutional investors. 3.3% of Aktis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Veradermics	N/A	N/A	N/A

Aktis Oncology presently has a consensus price target of $34.60, indicating a potential upside of 44.83%. Veradermics has a consensus price target of $153.00, indicating a potential upside of 39.32%. Given Aktis Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Aktis Oncology is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Aktis Oncology and Aktis Oncology both had 5 articles in the media. Aktis Oncology's average media sentiment score of 1.06 beat Veradermics' score of 0.39 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veradermics has lower revenue, but higher earnings than Aktis Oncology. Veradermics is trading at a lower price-to-earnings ratio than Aktis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$8.28M	154.14	-$63.73M	-$0.38	N/A
Veradermics	N/A	N/A	N/A	-$1.32	N/A

Summary

Aktis Oncology beats Veradermics on 9 of the 10 factors compared between the two stocks.

How does Aktis Oncology compare to Legend Biotech?

Aktis Oncology (NASDAQ:AKTS) and Legend Biotech (NASDAQ:LEGN) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

Aktis Oncology has higher earnings, but lower revenue than Legend Biotech. Aktis Oncology is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$8.28M	154.14	-$63.73M	-$0.38	N/A
Legend Biotech	$1.14B	3.62	-$296.80M	-$0.68	N/A

Aktis Oncology has a net margin of 0.00% compared to Legend Biotech's net margin of -21.98%. Aktis Oncology's return on equity of 0.00% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Legend Biotech	-21.98%	-24.92%	-14.87%

28.8% of Aktis Oncology shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 3.3% of Aktis Oncology shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Aktis Oncology had 1 more articles in the media than Legend Biotech. MarketBeat recorded 5 mentions for Aktis Oncology and 4 mentions for Legend Biotech. Aktis Oncology's average media sentiment score of 1.06 beat Legend Biotech's score of 0.41 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aktis Oncology presently has a consensus target price of $34.60, suggesting a potential upside of 44.83%. Legend Biotech has a consensus target price of $55.38, suggesting a potential upside of 149.26%. Given Legend Biotech's higher possible upside, analysts clearly believe Legend Biotech is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Aktis Oncology beats Legend Biotech on 11 of the 16 factors compared between the two stocks.

Get Aktis Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKTS vs. The Competition

Export

Metric	Aktis Oncology	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.28B	$3.11B	$7.24B	$12.26B
Dividend Yield	N/A	15.21%	40.99%	9.79%
P/E Ratio	-62.87	13.16	23.62	23.64
Price / Sales	154.14	2,709.07	132.14	89.57
Price / Cash	N/A	25.90	165.01	59.64
Price / Book	-8.27	9.39	12.77	6.07
Net Income	-$63.73M	-$34.07M	$120.21M	$331.99M
7 Day Performance	-4.02%	0.44%	-0.98%	-0.63%
1 Month Performance	-23.31%	0.09%	-2.00%	-2.00%
1 Year Performance	N/A	9.86%	9.75%	13.62%

Aktis Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKTS Aktis Oncology	2.3326 of 5 stars	$23.89 -0.5%	$34.60 +44.8%	N/A	$1.28B	$8.28M	N/A	76	News Coverage Analyst Downgrade
KNSA Kiniksa Pharmaceuticals International	2.8989 of 5 stars	$62.58 -2.1%	$65.14 +4.1%	+133.6%	$4.81B	$677.56M	69.53	220	News Coverage Upcoming Earnings Analyst Forecast
INDV Indivior	2.1318 of 5 stars	$39.12 -3.5%	$40.29 +3.0%	+141.1%	$4.77B	$1.24B	20.06	1,051	News Coverage Upcoming Earnings
CRSP CRISPR Therapeutics	3.3729 of 5 stars	$46.99 -1.7%	$67.78 +44.2%	-29.5%	$4.53B	$3.51M	N/A	460	News Coverage Positive News Analyst Forecast
MANE Veradermics	2.7288 of 5 stars	$106.90 -4.0%	$153.00 +43.1%	N/A	$4.47B	N/A	N/A	19

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKTS) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aktis Oncology (AKTS) Competitors

AKTS vs. KNSA, INDV, CRSP, MANE, and LEGN

How does Aktis Oncology compare to Kiniksa Pharmaceuticals International?

Summary

How does Aktis Oncology compare to Indivior?

Summary

How does Aktis Oncology compare to CRISPR Therapeutics?

Summary

How does Aktis Oncology compare to Veradermics?

Summary

How does Aktis Oncology compare to Legend Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTS vs. The Competition

Aktis Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aktis Oncology (AKTS) Competitors

AKTS vs. KNSA, INDV, CRSP, MANE, and LEGN

How does Aktis Oncology compare to Kiniksa Pharmaceuticals International?

Do institutionals and insiders have more ownership in KNSA or AKTS?

Is KNSA or AKTS more profitable?

Does the media refer more to KNSA or AKTS?

Which has preferable earnings and valuation, KNSA or AKTS?

Do analysts rate KNSA or AKTS?

Summary

How does Aktis Oncology compare to Indivior?

Which has preferable valuation and earnings, INDV or AKTS?

Do insiders & institutionals believe in INDV or AKTS?

Is INDV or AKTS more profitable?

Does the media favor INDV or AKTS?

Do analysts prefer INDV or AKTS?

Summary

How does Aktis Oncology compare to CRISPR Therapeutics?

Which has better valuation & earnings, CRSP or AKTS?

Do analysts rate CRSP or AKTS?

Do institutionals and insiders hold more shares of CRSP or AKTS?

Does the media refer more to CRSP or AKTS?

Is CRSP or AKTS more profitable?

Summary

How does Aktis Oncology compare to Veradermics?

Do insiders and institutionals have more ownership in AKTS or MANE?

Is AKTS or MANE more profitable?

Do analysts prefer AKTS or MANE?

Does the media favor AKTS or MANE?

Which has stronger earnings & valuation, AKTS or MANE?

Summary

How does Aktis Oncology compare to Legend Biotech?

Which has preferable valuation & earnings, AKTS or LEGN?

Is AKTS or LEGN more profitable?

Do institutionals and insiders hold more shares of AKTS or LEGN?

Does the media favor AKTS or LEGN?

Do analysts recommend AKTS or LEGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTS vs. The Competition

Aktis Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools